U.S. Stock Night Market Opening Movements

Modular Medical, up 8.38% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Quoin Pharmaceuticals, down 6.86% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Top Gainers in the U.S. Night Market

Jianzhi Education up 36.09% in the night market. Based on recent key news:

1. On August 28, Jianzhi Education Technology Group Co., Ltd. released its latest financial report through the EDGAR system of the U.S. Securities and Exchange Commission. The report shows a significant improvement in the company's performance, driving the stock price up.

2. On August 28, Jianzhi Education announced a new strategic cooperation agreement, which is expected to significantly expand its market share and further enhance investor confidence.

3. On August 28, analysts generally raised their earnings forecasts for Jianzhi Education, expecting continued growth in performance over the next few quarters, with positive market reactions. The education sector has performed strongly recently, with evident capital inflows.

BioLineRx up 9.23% in the night market. Based on recent news:

1. On August 28, BioLineRx announced the completion of an important agreement focused on developing transformative treatments for tumors and rare diseases. This news boosted market confidence, driving the stock price up.

2. On August 28, BioLineRx announced a registered direct offering and concurrent private placement, expected to raise $3.75 million. The company will sell 1.35 million ADS at a price of $2.78 per share and issue new warrants covering up to 2.02 million ADS, with an exercise price of $2.78. This offering is expected to be completed on August 31, with net proceeds to be used for R&D, working capital, and general corporate purposes.

3. On August 28, analysts expect BioLineRx's quarterly revenue to grow by 87.1%, reaching $477,000, a significant increase from $255,000 in the same period last year. Analysts are optimistic about the company's future performance, further driving the stock price up. The biopharmaceutical industry has performed strongly recently, with evident capital inflows.

Tenax Therapeutics up 8.92% in the night market. Based on recent key news:

1. On August 31, Tenax Therapeutics reported positive changes in biomarkers for the drug TNX-103. Right ventricular systolic pressure decreased by 4.4 mmHg, and NT-proBNP decreased by 47%, showing significant improvement in cardiac pressure, driving the stock price up. Source: GlobeNewswire

2. On August 29, Tenax Therapeutics released research results on TNX-103, showing that in participants with a baseline six-minute walk distance of less than 333 meters, the drug significantly increased walking distance by 26.3 meters, with statistical significance of p=0.0112 Enhanced market confidence. Source: GlobeNewswire

3. On August 29, the uncertainties in the global economy and financial markets, including tariff changes and geopolitical risks, affected the market environment for Tenax Therapeutics, but the company still maintains a positive product development momentum. Source: SEC filings The biotechnology industry has recently been active, with significant capital inflows